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Transient FGF stimulation of various cell types results in FGF memory—a sustained blockage of efficient proliferative response to FGF
and other growth factors. FGF memory establishment requires HDAC activity, indicating its epigenetic character. FGF treatment
stimulates proinflammatory NFkB signaling, which is also critical for FGF memory formation. The search for FGF-induced mediators of
FGF memory revealed that FGF stimulates HDAC-dependent expression of the inflammatory cytokine IL1a. Similarly to FGF, transient
cell treatment with recombinant IL1a inhibits the proliferative response to further FGF and EGF stimulation, but does not prevent FGF
receptor-mediated signaling. Interestingly, like cells pretreated with FGF1, cells pretreated with IL1a exhibit enhanced restructuring of
actin cytoskeleton and increased migration in response to FGF stimulation. IRAP, a specific inhibitor of IL 1 receptor, and a neutralizing
anti-IL1a antibody prevent the formation of FGF memory and rescue an efficient proliferative response to FGF restimulation. A similar
effect results following treatment with the anti-inflammatory agents aspirin and dexamethasone. Thus, FGF memory is mediated by
proinflammatory IL1 signaling. It may play a role in the limitation of proliferative response to tissue damage and prevention of wound-
induced hyperplasia.
J. Cell. Physiol. 231: 650–658, 2016.  2015 Wiley Periodicals, Inc.
We recently determined that transient FGF stimulation results
in a stable inhibition of proliferative response to repeated FGF
treatment (Poole et al., 2014). This phenomenon termed
“FGF memory” has been detected in fibroblasts, endothelial
cells, mesenchymal stem cells, and adipose-derived stem cells.
Cell stress occurring in damaged tissues can results in the
nonclassical release of FGF1 (Prudovsky et al., 2008). We
hypothesized that FGF memory may serve to moderate the
proliferative response after tissue damage, and thus prevent
hyperplasia and decrease scar formation. Establishment of FGF
memory depends on NFkB signaling and requires histone
deacetylase (HDAC) activity (Poole et al., 2014). Based on
these results, a study was undertaken to understand the
molecular mechanisms underlying FGF memory. We found
that FGF enhances the expression of interleukin (IL) 1a, and
this effect depends on HDAC activity. Similarly to FGF,
transient treatment with IL1a drastically inhibits the
proliferative response to subsequent stimulation with FGF but
does not interfere with FGF-promoted signaling and cell
migration. Moreover, cell pretreatment with both FGF1 and
IL1a blocks the proliferative response to an unrelated growth
factor, EGF. FGFmemory is abolished by IRAP, the competitive
inhibitor of IL1 receptor type I, and a specific neutralizing
antibody against IL1a. In addition, anti-inflammatory agents
aspirin and dexamethasone eliminate it. Collectively, these
results show that FGF memory is mediated by IL1a production
resulting in enhanced inflammatory signaling.
Materials and Methods
Cell cultures
Swiss 3T3 (ATCC, Manassas, VA) cells and mouse lung endothelial
cells Le II (Friesel and Maciag, 1988) were maintained in DMEM
(HyClone, Logan, UT) supplemented with 10% bovine calf serum
(HyClone) and 1% antibiotic-antimycotic mixture (GIBCO, Grand
Island, NY). Quiescence was induced by culturing cells in DMEM
containing 0.2% bovine calf serum and 5 units/mL heparin
(Sigma, St. Louis, MO).
Cell treatment
Prior to stimulation, cells were transferred for 48 h to quiescence
(Q) medium: DMEM with 5 units/mL heparin and 0.2% bovine calf
serum. This basic medium was used in all types of stimulation.
Upon induction of quiescence as well as withdrawal of growth
factors, the cells were washed twice with DMEM medium
containing 5 units/mL heparin.
Recombinant human FGF1 was prepared as described (Forough
et al., 1991) and applied at 10 ng/mL. Human recombinant EGF
(Lonza, Portsmouth, NH) and IL1a (Roche, Nutley, NJ) were used
Contract grant sponsor: NIH, Maine Cancer Foundation;
Contract grant number: NIH HL35627, NIH P30 GM103392.
*Correspondence to: Igor Prudovsky, Center for Molecular
Medicine, Maine Medical Center Research Institute, Maine Medical
Center, 81 Research Dr., Scarborough, ME 04107.
E-mail: prudoi@mmc.org
Manuscript Received: 4 February 2015
Manuscript Accepted: 24 July 2015
Accepted manuscript online in Wiley Online Library
(wileyonlinelibrary.com): 27 July 2015.
DOI: 10.1002/jcp.25111
ORIGINAL RESEARCH ARTICLE 650
J o u r n a l  o fl
Cellular
Physiology
© 2 0 1 5 W I L E Y P E R I O D I C A L S , I N C .
at 10 ng/mL. Human recombinant IRAP (Roche) and neutralizing
antibodies against mouse IL1a (R&D,Minneapolis, MN)were used
at 600 or 300 ng/mL.
The following chemical compounds were used: aspirin
(acetylsalicylic acid) (Sigma), dexamethasone (Sigma), trichostatin
A (TSA) (Sigma) and panabinostat (Selleck, Houston, TX).
Dna synthesis study
Throughout the final 36 h of each stimulation condition, the cells
were exposed to 10mg/mL bromodeoxyuridine (BrdU) (Sigma).
Once stimulation schedules were completed, the cells were fixed
for a minimum of 10min in 100% ethanol, washed with PBS, and
DNA was denatured by incubation in 1N HCl at 55°C for 30min.
The residual acid was then washed with PBS. Non-specific binding
of antibodies was prevented by a 30min pre-exposure to blocking
buffer (5% bovine albumin, 0.1% Triton X-100, 0.1% sodium azide
in PBS), followed by an 1 h incubation in a 1:500 dilution of
monoclonal mouse anti-BrdU antibody (Dako, Carpinteria, CA) in
blocking buffer. The cells were then washed with PBS and
incubated for 30min in 1:500 dilution of Alexa 546-conjugated
anti-mouse IgG antibodies (Invitrogen). Counting of BrdU-positive
nuclei in cell populations was performed using an Olympus IX70
microscope with a combination of fluorescence and phase
contrast. Two coverslips were studied per each experimental
point. For each coverslip, 500 nuclei were counted; the number of
fluorescent nuclei was recorded to acquire BrdU incorporation
percentages.
Cell migration assay
Linear scratches in cell monolayers weremade using a 1mL pipette
tip. Photographs of scratches were taken at 0 and 24 h after
monolayer wounding. Per each experimental condition, three
independent wells were studied, and in each of them fifteen
microscopic fields were photographed using the 10 X objective.
Themean distances covered by the migrating fronts of monolayers
and corresponding SEM were calculated.
Confocal fluorescence microscopy
The effects of FGF stimulation on the actin skeleton of na€ıve and
IL1a-pretreated Swiss 3T3 cells were studied using confocal
fluorescence microscopy. The cells were fixed with 4% neutral
formalin, pre-incubated in blocking permeabilizing buffer (PBS with
5% BSA and 0.1% Triton X100), and then stained with Oregon
green-conjugated phalloidin and TOPRO3 (both from Invitrogen,
Carlsbad, CA). Cell images were taken using Leica SP8 confocal
microscope at the MMCRI confocal microscopy facility.
Immunoblot analysis
Lysates were prepared from cell monolayers after various
schedules involving IL1a and FGF1 stimulation. The cells were
washed and scraped in ice-chilled PBS and centrifuged for
collection at 2,500 rpm for 10min. NPB buffer (20mM Tris-HCl
(pH 7.4), 250mM sucrose, 60mM KCl, 20mM EDTA, 1.5M NaCl,
1% TritonX-100, 0.1% deoxycholic acid, and a 1:50 dilution of
protease inhibitor cocktail from Sigma) was used to lyse the cells.
Relative protein concentrations were determined with Coomassie
Plus Protein Assay Kit (Pierce, Rockford, IL) using a DU 640
spectrophotometer (Beckman, Fullerton, CA) at an excitation
wavelength of 595 nm. The lysate was then mixed with an equal
volume of SDS–PAGE sample buffer and incubated at 95°C for
10min. Equivalent sample amounts were resolved by 12% PAGE
and transferred to membranes Hybond-P (GE Healthcare, Little
Chalfont, UK). The membranes were blocked in 5% fat-free dry
milk diluted in TBS-Tween buffer at 42°C for 2 h, and then blotted
with the appropriate primary mouse or rabbit antibody overnight
at 4°C.
Membranes blotted with mouse anti-b-actin antibodies (Sigma)
served as loading controls. Antibodies against the following
proteins were used: rabbit antibodies against phosphorylated
Erk1/2 (Sigma) and against cyclin D1 (Santa Cruz Biotechnologies,
Santa Cruz, CA), and mouse monoclonal antibodies recognizing
cyclin A (Millipore, Temecula, CA). The bound primary antibodies
were visualized using horseradish peroxidase-conjugated goat
antibodies against rabbit or mouse IgG (BioRad, Hercules, CA) and
the ECL detection system (Amersham, Piscataway, NJ).
RT–PCR
RNA was prepared from Swiss 3T3 cells using the RNeasy kit
(Qiagen, Hilden, Germany). Expression of IL1b and IL1a was
assessed by RT-PCR using the SuperScript kit (Invitrogen). The
following pairs of primers were utilized:
IL1a: as. -50-GTC TCA TGA AGT GAG CCA TAG C-30,
s. -50-CAA GAT GGC CAA AGT TCG TGA C-30.
IL1b: as. -50-CAG GAC AGG TAT AGA TTC TTT CTT TT-30,
s. -50-ATG GCA ACT GTT CCT GAA CTC AAC T-30.
b-actin: as. -50-GTCTCAAACATGATCTGGG-30, s. 50-AGA
AAA TCT GGC ACC ACA CC-30.
For qRT-PCR, we used the same IL1a primers and the following
cyclophilin primers:
as. -50-CAG TGC TCA GAG CTC GAA AG-30, s. -50-CCA
CCG TGT TCT TCG ACA T-30.
Elisa
IL1a concentration in cell lysates was determined using an ELISA
kit from eBioscience (San Diego, CA) according to the instructions
of the manufacturer.
Statistical analysis
Each experiment was repeated at least three times with consistent
results. In the studies analyzing DNA synthesis, percentage of
BrdU-labeled cells with 95% confidence interval was calculated for
each condition. In qRT-PCR and ELISA studies of IL1a expression
and in the studies of cell growth and migration, Student’s t test was
used to assess the significance of observed effects.
Results
FGF induces the expression of IL1a
The observations that FGF stimulation activates NFkB
signaling, and establishment of FGF memory depends on NFkB
pathway (Poole et al., 2014) indicated that FGF may induce the
expression of a proinflammatory cytokine. Interestingly, IL1a, a
potent inducer of inflammation and activator of NFkB signaling,
represses cell proliferation (Ohmori et al., 1988; Ikeda et al.,
1991) and plays a key role in some cases of cell senescence
(Maier et al., 1990; McCarthy et al., 2013).We used RT-PCR to
assess the effect of FGF1 stimulation on the expression of
proinflammatory cytokines and inducers of NFkB signaling,
IL1a, and IL1b, in Swiss 3T3 cells (Fig. 1A). While IL1b
expression remained unchanged, FGF1 stimulated the
expression of IL1a. qRT-PCR study has shown a 20-fold
induction of IL1a by FGF (Fig. 1B). Interestingly, the induction
of IL1a expression by FGF1 was abolished by the HDAC
inhibitor panabinostat (Fig. 1C). The RT-PCR results were
confirmed by determining the IL1a content in the lysates of
Swiss 3T3 cells stimulated with FGF1 in presence or absence of
HDAC inhibitors (Fig. 1D). It is noteworthy that the
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concentration of IL1a in the cell lysates after repeated FGF1
stimulation was approximately five times higher than after the
primary stimulation. Thus, FGF induces the expression of IL1a
in an HDAC-dependent manner.
Transient pretreatment with IL1a prevents proliferative
response to FGF and EGF
Because FGF1 induces the expression of IL1a, we assessed
whether similar to transient FGF1 stimulation, transient
application of IL1a to Swiss 3T3 cells prevents proliferative
response to further FGF stimulation. The following schedules
of cell treatment were applied: QQ – 168 h of quiescence;
QF – 132 h quiescence, 36 h FGF1; QIQQ – 48 h quiescence,
36 h IL1a, 84 h quiescence; QIQF – 48 h quiescence, 36 h IL1a,
48 h quiescence, 36 h FGF1. BrdU incorporation during the last
36 h of each schedule was determined (Fig. 2A). IL1a
pretreatment (QIQF) resulted in a 10-fold decrease of DNA
synthesis in comparison to FGF1 stimulation of naive quiescent
cells (QF) (Fig. 2B). In a series of similar experiments, we found
that transient FGF1 and IL1a stimulations inhibited the
proliferative response to epidermal growth factor (EGF)
(Fig. 2C,D).
Transient pretreatmentwith IL1a does not interferewith
the activation of Erk1/2 and induction of cyclin D in
response to FGF stimulation but prevents the induction of
cyclin A
To understand the mechanisms through which the
pretreatment of FGF1 inhibits growth factor-induced
proliferation, we used immunoblotting to assess the
Fig. 1. FGF1 induces IL1a expression in an HDAC-dependent manner. A: Confluent Swiss 3T3 cell cultures were incubated for 48h in
quiescence medium (0.2% serum) and then transferred for 36h to quiescence medium with (QF) or without (QQ) 10ng/mL FGF1. Expression
of IL1b and IL1a was determined by RT-PCR. B: Cells were treated similarly to A and IL1a expression was determined by qRT-PCR.
Indicates P< 0.01. C: Cells were treated similarly to A with an additional condition, when FGF stimulation was performed in the presence of
200nM panabinostat (QF/PAN). Expression of IL1a was determined by RT-PCR. D: Cells were treated similarly to C except that quiescence
was extended to 168h in QQ, and to 132h in QF and QF/PAN, and two additional schedules were added: (i) repeated FGF1 stimulation
(QFQF), when following the primary FGF1 stimulation cells were transferred for 48h to quiescence medium and after that restimulated for
36h with FGF1; (ii) FGF1 stimulation of na€ıve cells in presence of 300nM trichostatin A (QF/TSA). Cell lysates were prepared and equalized
based on total protein concentration. The concentration of IL1a in the equalized lysates was determined using an ELISA kit. Indicates
P< 0.01.
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Fig. 2. Transient treatment with IL1a results in a stable repression of proliferative response to growth factors. A: Schedules of cell
stimulations with IL1a, FGF1, and EGF (explanation in the text). BrdU labeling of Swiss 3T3 cells was performed during the final 36 h of each
stimulation schedule. B: Acute repression of proliferative response to FGF1 (10 ng/mL) after transient pretreatment with IL1a (10 ng/mL) and
the intermediate 48h period of quiescence. C,D: Transient pretreatment with FGF1 (C) or IL1a (D) inhibits the proliferative response to EGF
(10ng/mL). In B, C, and D, the percentage of BrdU labeled cells with 95% confidence interval for each condition is shown. The experiments
were repeated at least three times and the results of representative experiments are presented.
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signaling events and expression of key cell cycle proteins in
response to FGF1 stimulation of IL1a-pretreated (QIQF)
and na€ıve (QF) Swiss 3T3 cells. Thirty minutes after final
FGF1 stimulation, the phosphorylation of Erk1/2 reflecting
the early signaling downstream of FGFR was identical in
both QIQF and QF cells (Fig. 3A). The same was true for the
expression of cyclin D1 24 h after stimulation, a period
corresponding to late G1/early S phase after the exit from
quiescence (Fig. 3B). In contrast, unlike naive cultures, cells
with IL1a history failed to express cyclin A, the key
regulator of the S-phase initiation and transition, in
response to 24 h FGF stimulation (Fig. 3B).
IL1a pretreatment enhances the restructuring of actin
cytoskeleton and cell migration in response to FGF
stimulation
Cells transiently treated with FGF respond to FGF
restimulation by enhanced actin cytoskeleton reorganization
and migration (Poole et al., 2014). We used phalloidin staining
to compare the status of the actin cytoskeleton after FGF
treatment of na€ıve (QF) and IL1a-prestimulated Swiss 3T3
(QIQF) cells. Confocal fluorescence study demonstrated a
stronger formation of actin fibers in cells with the history of
IL1a treatment (Fig. 4A). In agreement with these results, the
study of wounded monolayers showed that QIQF cells
exhibit a faster migration than cells in QF populations
(Fig. 4B).
FGF memory depends on IL1 receptor signaling
The induction of IL1a expression by FGF1 and the similarity
between the effects of FGF1 and IL1a pretreatment on
proliferative and migratory response to FGF stimulation
indicate that FGF memory could be dependent on IL1 signaling.
To assess this hypothesis, we determined the effect of IRAP, a
specific competitive antagonist of IL1 receptor type I, on FGF
memory. When IRAP was applied throughout the QFQF
schedule of a typical FGF memory experiment, it completely
rescued the proliferative response of Swiss 3T3 cells after
repeated FGF1 stimulation (Fig. 5A).
Neutralization of IL1a rescues the proliferative response
to the secondary FGF stimulation
To assess the role of IL1a in FGF memory, we evaluated the
effect of a specific neutralizing anti-IL1a antibody upon the
proliferative response of Swiss 3T3 cells to secondary FGF
stimulation. We found that DNA synthesis after repeated
FGF treatment was rescued when anti-IL1a antibodies were
present throughout the QFQF experimental schedule
(Fig. 5B).
Anti-inflammatory drugs rescue the proliferative
response to the secondary FGF stimulation
IL1a is a potent proinflammatory cytokine. To elucidate
whether inflammatory signaling is required for FGF memory,
we used two anti-inflammatory drugs: aspirin and
dexamethasone. Both of them restored the proliferative
response of Swiss 3T3 cells to the secondary FGF
stimulation (Fig. 6A,B). Decreasing the concentrations of
aspirin and IL1a resulted in weaker rescuing effects
(Supplementary Figure 1).
The rescuing effects of aspirin and dexamethasone on DNA
synthesis were confirmed in FGF restimulation experiments
using Le II mouse lung endothelial cells (Fig. 7A). Moreover, in
special experiments where the time of secondary FGF
stimulation was extended to 2 days, we detected a significant
increase of LeII cell numbers upon the treatment with aspirin
and dexamethasone (Fig. 7B,C).
Discussion
The earlier observation that transient stimulation with FGF
results in a stable and potent inhibition of proliferative
response to repeated growth factor stimulation (Poole et al.,
2014) encouraged us to elucidate the key molecular
determinant(s) of this phenomenon that had been termed FGF
memory. The present study shows that IL1a plays a critical role
in FGF memory. The following results underlie this conclusion:
(i) FGF treatment results in a HDAC-dependent IL1a
expression; (ii) IL1a stimulation generates a cell phenotype
similar to that observed in FGF-pretreated cells, i.e., strongly
inhibited proliferative and enhanced migratory response to
growth factor stimulation; (iii) IRAP and specific neutralizing
anti-IL1a antibodies inhibit FGF memory.
It has long been known that IL1a exhibits anti-proliferative
effects in non-transformed cells (Ohmori et al., 1988; Ikeda
et al., 1991). In particular, it was found that senescence of
human endothelial cells can be significantly delayed by the
inhibition of IL1a expression (Maier et al., 1990). In recent
years, IL1a was identified as a key determinant of the
senescence-associated secretory cell phenotype, which is
characterized by the inhibition of proliferation and production
of several proinflammatory cytokines in addition to IL1a
(McCarthy et al., 2013).
We have earlier reported that transient FGF stimulation
results in a sustained activation of NFkB signaling, which is
critical for FGF memory establishment (Poole et al., 2014).
IL1a (Niu et al., 2004; Melisi et al., 2009) and FGF (Muddasani
et al., 2007; Salazar et al., 2014) have been demonstrated to
activate the proinflammatory NFkB pathway. Moreover,
IL1a expression and NFkB signaling constitute an
autoregulatory feedback loop that maintains IL1a production
(Niu et al., 2004). Proinflammatory signaling can result in the
inhibition of DNA synthesis (Vlahos and Stewart, 1999).
Concurrently, we have shown that the anti-inflammatory
drugs, aspirin and dexamethasone, abolish IL1a-mediated
FGF memory. Thus, FGF-induced IL1a expression and
Fig. 3. FGF-induced proliferative signaling in Swiss 3T3 cells
pretreated with IL1a. Phosphorylation of Erk1/2 (A) and expression
of cyclins D1 and A (B) in na€ıve (QF) and IL1a-pretreated (QIQF)
Swiss 3T3 cells. The duration of final FGF1 stimulation was 30 min
(A) or 24h (B). Total cell lysates were resolved by SDS–PAGE and
immunoblotted for phospho-Erk1/2, cyclin D1, cyclin A, or b-actin.
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proinflammatory signaling limit the proliferative response to
continuous FGF stimulation. The experiments involving
transient cell treatment with IL1a demonstrated a sustained
inhibition of proliferative response to FGF and EGF
stimulation. Similar to earlier reported experiments with
FGF restimulation (Poole et al., 2014), cells pretreated with
IL1a respond to FGF by Erk1/2 phosphorylation and cyclin
D1 expression. Moreover, their cytoskeletal and migratory
responses to FGF are significantly stronger than in na€ıve cells.
These results indicate that FGFR-mediated signaling,
progression from quiescence to G1 phase as well as
morphological and migratory changes are resistant to IL1a
or increased by it. Indeed, IL1 signaling enhances cell
migration in the course of inflammation (Mitchell et al.,
Fig. 4. Cell pretreated with IL1a respond to FGF with an enhanced restructuring of the actin cytoskeleton and accelerated migration. A:
IL1a pretreatment results in an exaggerated restructuring of the actin cytoskeleton in response to FGF stimulation of Swiss 3T3 cells.
Following formalin fixation (36h after final FGF stimulation), cells were co-stained with Oregon green-phalloidin for F-actin (green) and DAPI
for DNA (blue), and studied using a confocal microscope. Bar 25mm. B: A standard experiment with FGF1 stimulation after IL1a
pretreatment was performed. At the end of the intermediate quiescence period, linear scratches in cell monolayers were made as described
in Experimental Procedures and then the usual stimulation schedules were followed. Photographs of scratches were taken at 0 and 24h after
monolayer wounding. Mean distances (with corresponding SEM) covered by migrating monolayer fronts by 24 h are presented with
indicating P< 0.01.
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2007). On the other hand, FGF-induced IL1a prevents DNA
replication. The mechanisms of the sustained inhibition of
proliferative response in cells transiently treated with IL1a
and FGF1 require further studies. The inability of such cells
to express cyclin A in response to FGF indicates the blockage
of cell cycle events immediately preceding the onset of the S
phase.
FGF memory and induction of IL1a expression require not
only NFkB signaling but also HDAC activity. Deacetylation of
NFkB p65 is required for its nuclear translocation and
retention and thus for efficient NFkB signaling (Grabiec
et al., 2012; Liu and McCall, 2013; Ziesche et al., 2013;
Zhang et al., 2015). FGF memory could be dependent on
HDAC-mediated histone deacetylation or on HDAC-
dependent activation of NFkB signaling or on both. As we have
reported (Poole et al., 2014), FGF does not change the
expression of major HDACs. Thus, the search for a specific
HDAC involved in FGF1memory followed by the identification
of its mechanism of action requires a comprehensive siRNA
knockdown screen study involving the assessment of FGF
memory establishment, NFkB signaling activity and IL1a
expression.
The significance of FGF memory for in vivo processes
remains to be elucidated. This phenomenon could play a role in
the regulation of the proliferative response during repair of
tissue damage. It is noteworthy that liver regeneration after
partial hepatectomy is accompanied by the increase of IL1
expression, which limits cell proliferation and prevents
hyperplasia (Boulton et al., 1997; Sgroi et al., 2011). It is also
interesting that endothelial-specific overexpression of FGF1 in
transgenic mice paradoxically results not in the improvement
of post-ischemic kidney repair, but in the inhibition of
reparative processes and increased inflammation (Kirov et al.,
2012). We hypothesize that FGF1 memory mediated by IL1a
production may regulate the repair of damaged tissues through
the limitation of cell proliferation and enhancement of cell
migration, which decrease scarring and help restore the normal
tissue structure.
Fig. 5. Blockage of IL1 signaling inhibits FGF memory. A: IRAP, the
inhibitor of IL1 receptor type I rescues the proliferative response of
Swiss 3T3 cells to repeated FGF1 stimulation. QQ – quiescent cells,
QF – na€ıve cells stimulated with FGF1, QFQF – cells restimulated
with FGF1 (for details see Fig. 2A). Additional schedules: (i) QF/irap
– 600ng IRAP present during the stimulation of na€ıve cells; (ii)
QFirapQF – 600 ng/mL IRAP during the primary FGF1 stimulation;
(iii) QFQF(irap) – 600 ng/mL IRAP present starting from the first
FGF1 stimulation to the end of restimulation. B: Neutralizing
antibodies against mouse IL1a rescue the proliferation of Swiss 3T3
cells restimulated with FGF1. QFQF (neut. Ab) 300ng/mL
neutralizing antibody present starting from the first FGF1
stimulation to the end of restimulation. In A and B, the percentage
of BrdU labeled cells with 95% confidence interval is shown for each
condition. In each case, the experiments were triplicated, and the
results of a representative experiment are shown.
Fig. 6. Anti-inflammatory agents aspirin (A) and dexamethasone
(B) suppress FGF memory in Swiss 3T3 cells. QQ – quiescent cells,
QF – na€ıve cells stimulated with FGF1, QFQF – cells restimulated
with FGF1 (for details see Fig. 2A). Additional schedules in A: (i) QF/
asp 1mM aspirin present during the FGF1 stimulation of na€ıve
cells; (ii) QFQF(asp) 1mM aspirin present starting from the first
FGF1 stimulation to the end of restimulation. Additional schedules
in B: (i) QF/dex 1mM dexamethasone present during the FGF1
stimulation of na€ıve cells; (ii) QFQF(Dex) 1mM dexamethasone
present starting from the first FGF1 stimulation to the end of
restimulation. In A and B, the percentage of BrdU labeled cells with
95% confidence interval is shown for each condition. In each case,
the experiments were triplicated, and the results of a representative
experiment are shown.
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